- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Tesh Khullar on the Importance of Community Oncology Patients Being Involved in Clinical Trials
Community oncologists face a challenge in getting patients into clinical trials, but new technology could help them get access to those trials, explained Tesh Khullar, senior vice president of provider solutions at Flatiron Health.
Community oncologists face a challenge in getting patients into clinical trials, but new technology could help them get access to those trials, explained Tesh Khullar, senior vice president of provider solutions at Flatiron Health.
Transcript (slightly modified)
What is the importance of getting patients treated at community oncology practices more involved in clinical trials?
Right now, in the academic setting and in the hospital setting, 10% of all of the accruals come from them, and it’s this belief that the community oncology practices cannot actually accrue patients at scale. So, we have a tech solution that we think is going to help disrupt that because if we can actually get the lower cost model better for patients-equal-outcomes, to actually accrue more patients, we do believe that pharmaceutical manufacturers, co-ops, and other organizations will go back to community oncology, which once again, is the better mechanism of care and more cost efficient. We want to be able to help community oncology level the field form the clinical trials perspective and get access to a lot of the same trials that only academics get, using technology.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More
